Skip to content

Cambridge, MA (March 28, 2006) - Ensemble Discovery Corporation today announced the appointment of Laurence E. Reid, Ph.D. as Chief Business Officer. In this position, Dr. Reid will lead strategic business planning and corporate development activities for the Company. He will work closely with the other members of Ensemble’s executive team to align business strategies and research and development efforts.

“We are excited to have such a seasoned executive as Laurence coming to Ensemble Discovery. He has a unique set of skills and insight to help us bring our novel technology to the market,” said Richard F. Begley, Ph.D., Ensemble Discovery’s CEO.

“I have had the pleasure of working with some of the best people and technology in the pharmaceutical and biotech industries, and recognized in Ensemble Discovery the vision and diverse product opportunities from which to build a great company," Dr. Reid said. "I am looking forward to working with the Ensemble team to translate the potential of the technology platform into novel products and to build a valuable and innovative business.”

Dr. Reid has over 20 years of diverse business and science experience in the life sciences field. His experience includes general management, strategic planning, commercial development and business development. Most recently, Dr. Reid was Chief Executive Officer of a seed stage venture focused in the fields of inflammation and pain. Prior to this, he spent more than 10 years at Millennium Pharmaceuticals. Joining the company as an early employee in 1993, Dr. Reid advanced through a succession of positions of increasing responsibility at Millennium, initially in business development and culminating in his role as General Manager of Millennium Pharmaceuticals, Ltd., where he was the senior Millennium representative in Europe, providing the overall business strategy and leadership to Millennium’s Cambridge, UK drug discovery and development operation.

About Ensemble Discovery

Ensemble Discovery Corporation, located in Cambridge, MA, is developing a novel approach to chemical discovery based on a highly integrated set of processes that combine chemistry, biology and nanotechnology. Central to its approach is DNA Programmed Chemistry (DPC), an innovative method for chemical synthesis based on the groundbreaking work of Professor David Liu of Harvard University. Ensemble aims to generate new products that address significant unmet needs in therapeutics, detection and other specialty chemical markets.

For More Information, Contact:

Richard F. Begley, Ph.D.
Ensemble Discovery Corporation
(617) 492-6977